467 related articles for article (PubMed ID: 31221662)
1. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
3. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
4. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
[TBL] [Abstract][Full Text] [Related]
5. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
[TBL] [Abstract][Full Text] [Related]
6. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
7. Interactions of multiple gene alterations in colorectal liver metastases.
Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
[TBL] [Abstract][Full Text] [Related]
8. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
9. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
10. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
[TBL] [Abstract][Full Text] [Related]
11. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
12. Gene mutation and surgical technique: Suggestion or more?
Kawaguchi Y; Lillemoe HA; Vauthey JN
Surg Oncol; 2020 Jun; 33():210-215. PubMed ID: 31351766
[TBL] [Abstract][Full Text] [Related]
13. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
[TBL] [Abstract][Full Text] [Related]
14. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
15. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.
Sebagh M; Allard MA; Bosselut N; Dao M; Vibert E; Lewin M; Lemoine A; Cherqui D; Adam R; Sa Cunha A
Oncotarget; 2016 Apr; 7(16):21591-600. PubMed ID: 26943031
[TBL] [Abstract][Full Text] [Related]
16. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
17. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
19. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
20. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
